Oncolytic Virotherapy: Single Cycle Cures or Repeat Treatments? (Repeat Dosing Is Crucial!).
作者信息
Melcher Alan
机构信息
Institute of Cancer Research, Department of Radiotherapy and Imaging, London, UK.
出版信息
Mol Ther. 2018 Aug 1;26(8):1875-1876. doi: 10.1016/j.ymthe.2018.07.002. Epub 2018 Jul 14.
Abstract
摘要
相似文献
1
Oncolytic Virotherapy: Single Cycle Cures or Repeat Treatments? (Repeat Dosing Is Crucial!).
Mol Ther. 2018 Aug 1;26(8):1875-1876. doi: 10.1016/j.ymthe.2018.07.002. Epub 2018 Jul 14.
2
For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough).
Mol Ther. 2018 Aug 1;26(8):1876-1880. doi: 10.1016/j.ymthe.2018.07.003. Epub 2018 Jul 18.
3
Virotherapy--cancer targeted pharmacology.
Drug Discov Today. 2012 Mar;17(5-6):215-20. doi: 10.1016/j.drudis.2011.12.011. Epub 2011 Dec 16.
4
Oncolytic virotherapy as immunotherapy.
Science. 2021 Dec 10;374(6573):1325-1326. doi: 10.1126/science.abk3436. Epub 2021 Dec 9.
5
Oncolytic Immunotherapy.
Surg Oncol Clin N Am. 2019 Jul;28(3):419-430. doi: 10.1016/j.soc.2019.02.007. Epub 2019 Apr 5.
6
Integrating oncolytic viruses in combination cancer immunotherapy.
Nat Rev Immunol. 2018 Aug;18(8):498-513. doi: 10.1038/s41577-018-0014-6.
7
Role of NK cells in immunotherapy and virotherapy of solid tumors.
Immunotherapy. 2015;7(8):861-82. doi: 10.2217/imt.15.53. Epub 2015 Aug 28.
8
Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Future Oncol. 2022 Jan;18(2):245-259. doi: 10.2217/fon-2021-0802. Epub 2021 Nov 25.
9
Editorial: oncolytic viruses.
Curr Pharm Biotechnol. 2012 Jul;13(9):1731. doi: 10.2174/138920112800958797.
10
A mathematical model of oncolytic virotherapy with time delay.
Math Biosci Eng. 2019 Mar 6;16(4):1836-1860. doi: 10.3934/mbe.2019089.
引用本文的文献
1
PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma.
Cancer Cell Int. 2024 Jan 30;24(1):50. doi: 10.1186/s12935-024-03238-z.
2
Engineering approaches for innate immune-mediated tumor microenvironment remodeling.
Immunooncol Technol. 2023 Oct 6;21:100406. doi: 10.1016/j.iotech.2023.100406. eCollection 2024 Mar.
3
Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes.
Commun Biol. 2022 Dec 19;5(1):1385. doi: 10.1038/s42003-022-04254-3.
4
Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus.
Viruses. 2022 Oct 23;14(11):2327. doi: 10.3390/v14112327.
5
The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress.
Bioengineered. 2021 Dec;12(2):11847-11857. doi: 10.1080/21655979.2021.1999372.
6
Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
Int J Mol Sci. 2020 Sep 1;21(17):6347. doi: 10.3390/ijms21176347.
本文引用的文献
1
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
Mol Ther. 2018 Apr 4;26(4):1008-1019. doi: 10.1016/j.ymthe.2018.01.019. Epub 2018 Jan 31.
2
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Sci Transl Med. 2018 Jan 3;10(422). doi: 10.1126/scitranslmed.aam7577.
3
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
Trends Immunol. 2018 Mar;39(3):209-221. doi: 10.1016/j.it.2017.11.006. Epub 2017 Dec 20.
4
Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.
Mol Ther. 2014 Oct;22(10):1851-63. doi: 10.1038/mt.2014.118. Epub 2014 Jun 24.
5
Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia.
Clin Cancer Res. 2013 Jul 15;19(14):3832-43. doi: 10.1158/1078-0432.CCR-12-3199. Epub 2013 May 28.
6
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.
Sci Transl Med. 2012 Jun 13;4(138):138ra77. doi: 10.1126/scitranslmed.3003578.
7
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
Nature. 2011 Aug 31;477(7362):99-102. doi: 10.1038/nature10358.
8
VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.
Gene Ther. 2010 Jul;17(7):922-9. doi: 10.1038/gt.2010.82. Epub 2010 May 27.
9
Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.
Clin Cancer Res. 2009 Jul 1;15(13):4374-4381. doi: 10.1158/1078-0432.CCR-09-0334. Epub 2009 Jun 9.
10
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
Gene Ther. 2009 May;16(5):689-99. doi: 10.1038/gt.2009.29. Epub 2009 Mar 12.
Zotero 插件